查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030100

人類乳突病毒疫苗市場－全球產業規模、佔有率、趨勢、機會和預測：按類型、疾病、分銷管道、地區和競爭格局分類，2021-2031年

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type, By Disease, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球人類乳突病毒 (HPV) 疫苗市場預計將從 2025 年的 84.7 億美元成長到 2031 年的 141.2 億美元，複合年成長率為 8.89%。

人類乳突病毒(HPV)疫苗是生物製藥，旨在預防特定類型的人類乳突病毒（HPV）感染，這些病毒是子宮頸癌及相關疾病的主要原因。該市場的成長主要受全球HPV相關癌症發生率上升、公眾預防醫學意識增強以及各國政府主導的疫苗接種計劃穩步推進等因素驅動。世界衛生組織（WHO）指出，預計2024年，全球整體青少年女性HPV疫苗首次接種率將達31%。

市場概覽
預測期 2027-2031
市場規模：2025年 84.7億美元
市場規模：2031年 141.2億美元
複合年成長率：2026-2031年 8.89%
成長最快的細分市場 子宮頸癌
最大的市場 北美洲

此外，全球疫苗免疫聯盟（Gavi）等國際衛生組織的持續支持在開發中國家擴大疫苗分發方面發揮著至關重要的作用，而科學進步也為疫苗提供了更多病毒株的保護。儘管存在這些積極因素，但疫苗猶豫仍然是市場成長的主要障礙。這種猶豫往往是由錯誤訊息的傳播造成的，這會導致疫苗接種率下降，並阻礙更廣泛的免疫目標。

市場促進因素

政府主導的疫苗宣傳活動一直是全球人類乳突病毒（HPV）疫苗產業的主要驅動力，顯著提高了疫苗的可及性和接種率。這些全國性的努力使得疫苗得以廣泛分發和接種，尤其是在醫療基礎設施不足或個人收入較低的地區。將人類乳突病毒(HPV)疫苗納入國家醫療體系，透過確保穩定的需求和擴大覆蓋範圍，直接促進了市場成長。人類乳突病毒(HPV)疫苗重要的里程碑。該報告凸顯了這些項目在減輕HPV相關疾病的全球影響和避免預計140萬人死亡方面的重要性。

大眾對HPV及相關癌症的認知和意識提升，透過消除疑慮和促進健康習慣，對市場產生了顯著影響。透過醫療專業人員和社區網路進行有效的資訊傳播，能夠為大眾提供真實詳盡的訊息，從而建立信任並刺激疫苗需求。認知到病毒與癌症之間的關聯以及疫苗的預防作用，對於消除接種障礙至關重要。例如，2025年2月發表在《生殖健康》（Reproductive Health）雜誌上的一項研究顯示，在奈及利亞奧貢州接受調查的1012人中，82%的人僅通過為期五天的公共衛生宣傳活動才了解到人類乳突病毒(HPV)疫苗，這表明有針對性的教育對於提高疫苗接種率至關重要。這種日益成長的興趣也體現在企業收入上，例如默克預計2025年第四季其Gardasil的全球銷售額將達到10億美元。

市場挑戰

全球人類乳突病毒（HPV）疫苗市場成長面臨的主要障礙之一是公眾抵制，這主要是由於持續不斷的、基於錯誤訊息的宣傳活動造成的。這些誤導性活動經常散佈關於疫苗安全性和有效性的毫無根據的謠言，導致目標族群對疫苗產生懷疑和不願接種。因此，疫苗接種率較低，難以達到實現市場擴張目標和更廣泛的公共衛生目標所需的理想接種水準。

這個問題嚴重阻礙了跨區域的市場整合。一個明顯的例子是孟買當局的觀察結果（根據《印度快報》2026年4月報道）：在最近一次邦級人類乳突病毒(HPV)疫苗宣傳活動中，106,045名少女中只有568人參與。一線醫護人員明確指出，如此低的參與率是由於社群媒體上傳播的錯誤訊息所造成的。如此低的疫苗接種率限制了疫苗的採購和分發數量，最終限制了潛在收入，並減緩了全球人類乳突病毒(HPV)疫苗市場的發展。

市場趨勢

人類乳突病毒（HPV）疫苗的國際市場正受到目標年齡層和人口覆蓋範圍擴大的顯著影響，預防策略也不再局限於傳統的青少年女性目標群體。這一趨勢包括擴大後續疫苗接種宣傳活動，並放寬對年齡較大人群的接種資格標準，旨在增強對HPV相關疾病的廣泛免疫力。例如，香港衛生署於2026年1月在其《人類乳突病毒（HPV）疫苗後續計畫更新》中公佈了一項針對2004年至2008年間出生的合格的女性公民的特別後續疫苗接種宣傳活動的詳情，該計畫於2025年6月26日啟動第三階段。此類計劃擴大了目標人群，從而刺激了產品需求的成長。

另一個影響產業格局的重大轉變是男性人類乳突病毒 (HPV) 疫苗接種的日益重視。雖然最初的疫苗接種策略主要針對女性，因為女性與子宮頸癌密切相關，但隨著我們對該病毒如何導致男性癌症及其對群體免疫影響的認知不斷加深，這種策略正在改變。這種觀點的轉變正在推動性別中立疫苗接種指南的訂定，並加強鼓勵男性參與的宣傳活動。 2026 年 4 月 Medscape 發布的報告《美國疾病管制與預防中心委員會批准擴大人類乳突病毒(HPV)疫苗接種建議，男性接種年齡上限為 26 歲》突顯了這項變化。該報告指出，美國疾病管制與預防中心 (CDC) 的一個委員會決定將男性後續疫苗接種的建議年齡從 21 歲提高到 26 歲，與女性的既定年齡保持一致。男性人口的成長直接推動了市場的發展。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球人類乳突病毒疫苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（二價、四價、九價）
    • 特定疾病癌症（子宮頸癌、陰道癌和外陰癌、肛門癌、口咽癌（頭頸部）癌、生殖器濕疣）
    • 分銷管道（醫院及零售藥局、政府採購機構等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美人類乳突病毒疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲人類乳突病毒疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區人類乳突病毒疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲人類乳突病毒疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲人類乳突病毒疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球人類乳突病毒疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck & Co., Inc.
  • GSK plc.
  • Serum Institute of India Pvt. Ltd
  • SANOFI WINTHROP INDUSTRIE
  • Pfizer Inc.
  • Inovio Pharmaceuticals, Inc
  • Walvax Biotechnology Co., Ltd
  • Bharat Biotech International Limited
  • Johnson & Johnson Services, Inc.
  • Moderna, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 13006

The Global market for Human Papillomavirus vaccines is anticipated to expand from USD 8.47 Billion in 2025 to USD 14.12 Billion by 2031, experiencing a compound annual growth rate of 8.89%. HPV vaccines are preventive biological treatments created to guard against specific human papillomavirus strains, which are the main culprits behind cervical cancer and related diseases. This market growth is largely fueled by the rising global rates of HPV-linked cancers, growing public understanding of preventive health, and the strong execution of state-sponsored vaccination initiatives across the globe. As noted by the World Health Organization, the worldwide first-dose coverage rate for the human papillomavirus vaccine among adolescent girls reached an estimated 31% in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.47 Billion
Market Size 2031USD 14.12 Billion
CAGR 2026-20318.89%
Fastest Growing SegmentCervical Cancer
Largest MarketNorth America

Additionally, continuous backing from international health entities like Gavi, the Vaccine Alliance plays a crucial role in broadening vaccine availability in developing nations, complemented by scientific progress that provides protection against a wider array of viral strains. Even with these positive factors, vaccine hesitancy continues to be a significant obstacle to market growth. This reluctance is frequently driven by the spread of false information, which can slow down adoption rates and obstruct efforts to reach broader immunization goals.

Market Driver

State-sponsored vaccination campaigns serve as a primary catalyst for the global Human Papillomavirus vaccine industry, substantially increasing both availability and participation. These country-wide efforts enable widespread distribution and delivery of vaccines, particularly in regions constrained by inadequate medical infrastructure or low personal income. Integrating HPV shots into national healthcare frameworks directly boosts market growth by ensuring steady demand and facilitating extensive demographic reach. As highlighted in a November 2025 report by Gavi, the Vaccine Alliance titled 'Cervical cancer vaccines save over 1 million lives in lower-income countries', the significant milestone of vaccinating 86 million girls against HPV by the close of 2025 was achieved, averting roughly 1.4 million projected fatalities and underscoring the importance of such programs in lowering the worldwide impact of HPV-associated illnesses.

Heightened public knowledge and educational initiatives regarding HPV and its associated cancers strongly influence the market by combatting skepticism and encouraging preventive healthcare habits. Successful informational drives, delivered via medical professionals and local community networks, equip the public with factual details, thereby building trust and stimulating demand for the vaccine. Recognizing the connection between the virus and cancer, alongside the vaccine's protective benefits, is critical for breaking down adoption barriers. For instance, a February 2025 study in 'Reproductive Health' revealed that 82% of 1012 surveyed participants in Ogun State, Nigeria, were introduced to the HPV vaccine solely through a 5-day public health drive, illustrating the necessity of focused education to optimize immunization levels. This rising interest is evident in corporate revenues, as seen when Merck & Co., Inc. recorded global fourth-quarter sales of $1.0 billion for GARDASIL in 2025.

Market Challenge

A major hurdle restricting the growth of the global Human Papillomavirus vaccine sector is public reluctance, heavily driven by ongoing campaigns of false information. These misleading efforts frequently circulate baseless rumors concerning the safety and effectiveness of the immunization, breeding suspicion and a lack of willingness among intended demographics to get vaccinated. Consequently, this leads to diminished participation levels, making it difficult to attain the ideal immunization rates required to fulfill both market expansion objectives and broader public health milestones.

This issue substantially hinders market integration across multiple territories. A clear instance occurred in April 2026, when The Indian Express cited Mumbai authorities noting that a mere 568 out of 106,045 targeted teenage girls participated in a recent state-level HPV vaccination campaign. Health workers on the ground explicitly blamed this exceptionally poor turnout on false narratives spreading across social media networks. Such weak compliance with health initiatives restricts the number of doses purchased and distributed, ultimately capping potential financial gains and slowing the worldwide advancement of the HPV vaccine market.

Market Trends

The international market for Human Papillomavirus vaccines is being heavily shaped by the widening of age guidelines and demographic coverage, pushing protective strategies past the conventional demographic of teenage girls. This development involves the growth of catch-up initiatives and relaxed qualification standards for older demographics, with the goal of strengthening widespread immunity against illnesses tied to HPV. As an illustration, in January 2026, Hong Kong's Department of Health detailed a special catch-up campaign for qualifying female citizens born from 2004 to 2008 in its 'Human Papillomavirus (HPV) Vaccination Catch-up Programme Latest News', launching its third stage on June 26, 2025. Programs like these enlarge the eligible patient base, thereby stimulating greater product demand.

A further critical movement molding the industry is the rising prioritization of inoculating males against the Human Papillomavirus. While early immunization strategies were largely aimed at women because of the strong connection to cervical cancer, a deeper understanding of how the virus causes male cancers and affects herd immunity is altering this approach. This shift in perspective is prompting the rollout of gender-neutral vaccination guidelines and intensified campaigns to boost male participation. Highlighting this shift, an April 2026 Medscape report titled 'CDC Committee Votes to Expand HPV Vaccine Recommendations for Men Up to Age 26' noted that a committee within the US Centers for Disease Control and Prevention elected to raise the recommended catch-up vaccination age for men from 21 to 26, matching the established standards for women. This expansion in eligible male populations directly contributes to market growth.

Key Market Players

  • Merck & Co., Inc.
  • GSK plc.
  • Serum Institute of India Pvt. Ltd
  • SANOFI WINTHROP INDUSTRIE
  • Pfizer Inc.
  • Inovio Pharmaceuticals, Inc
  • Walvax Biotechnology Co., Ltd
  • Bharat Biotech International Limited
  • Johnson & Johnson Services, Inc.
  • Moderna, Inc.

Report Scope

In this report, the Global Human Papillomavirus Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Papillomavirus Vaccine Market, By Type

  • Bivalent
  • Quadrivalent
  • Nonavalent

Human Papillomavirus Vaccine Market, By Disease

  • Cervical Cancer
  • Vaginal and Vulvar Cancers
  • Anal Cancer
  • Oropharyngeal (Head and Neck) Cancers
  • Genital Warts

Human Papillomavirus Vaccine Market, By Distribution Channel

  • Hospitals and Retail Pharmacies
  • Government Suppliers
  • Others

Human Papillomavirus Vaccine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Papillomavirus Vaccine Market.

Available Customizations:

Global Human Papillomavirus Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Papillomavirus Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Bivalent, Quadrivalent, Nonavalent)
    • 5.2.2. By Disease (Cervical Cancer, Vaginal and Vulvar Cancers, Anal Cancer, Oropharyngeal (Head and Neck) Cancers, Genital Warts)
    • 5.2.3. By Distribution Channel (Hospitals and Retail Pharmacies, Government Suppliers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Human Papillomavirus Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Disease
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Human Papillomavirus Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Disease
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Human Papillomavirus Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Disease
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Human Papillomavirus Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Disease
        • 6.3.3.2.3. By Distribution Channel

7. Europe Human Papillomavirus Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Disease
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Human Papillomavirus Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Disease
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Human Papillomavirus Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Disease
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Human Papillomavirus Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Disease
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Human Papillomavirus Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Disease
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Human Papillomavirus Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Disease
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Human Papillomavirus Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Disease
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Human Papillomavirus Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Disease
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Human Papillomavirus Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Disease
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Human Papillomavirus Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Disease
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Disease
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Human Papillomavirus Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Disease
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Human Papillomavirus Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Disease
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Disease
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Human Papillomavirus Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Disease
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Human Papillomavirus Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Disease
        • 9.3.3.2.3. By Distribution Channel

10. South America Human Papillomavirus Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Disease
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Disease
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Human Papillomavirus Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Disease
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Human Papillomavirus Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Disease
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Human Papillomavirus Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck & Co., Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GSK plc.
  • 15.3. Serum Institute of India Pvt. Ltd
  • 15.4. SANOFI WINTHROP INDUSTRIE
  • 15.5. Pfizer Inc.
  • 15.6. Inovio Pharmaceuticals, Inc
  • 15.7. Walvax Biotechnology Co., Ltd
  • 15.8. Bharat Biotech International Limited
  • 15.9. Johnson & Johnson Services, Inc.
  • 15.10. Moderna, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer